[144] Beta Bionics, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 notice for Beta Bionics (BBNX) reports a proposed sale of 16,158 common shares through Merrill Lynch with an aggregate market value of $268,376.10. The filing lists 43,470,125 shares outstanding and an approximate sale date of 08/19/2025 on NASDAQ. The securities were acquired the same day (08/19/2025) via a stock option from Beta Bionics and payment is listed as cash. The filing also discloses a prior sale by Mark Hopman of 868 shares on 06/02/2025 for $15,529.00. The signer certifies they have no undisclosed material information and provides the standard Rule 10b5-1 and legal attestations.

Positive

• Regulatory compliance: The filer provides required disclosure including acquisition method, broker, and prior related sales, meeting Rule 144 reporting obligations.

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine insider notice for a small planned sale; discloses acquisition method and prior recent sale.

The Form 144 documents a proposed sale of 16,158 common shares valued at $268,376.10 against 43,470,125 shares outstanding, representing roughly 0.037% of outstanding shares, indicating the sale is immaterial to overall capitalization. The securities were acquired via a stock option the same day and will be sold through Merrill Lynch on NASDAQ. The filing meets disclosure requirements by reporting prior related sale activity (868 shares on 06/02/2025 for $15,529). From a trading-volume and market-impact perspective, this is a routine compliance filing rather than a material corporate event.

Corporate Governance Expert

TL;DR: Proper compliance with Rule 144; no indication of undisclosed material information.

The filer discloses the nature of acquisition (stock option from the issuer) and affirms the absence of material nonpublic information, which aligns with governance best practices for insider transactions. The contemporaneous acquisition and sale date is noted, and the notice identifies the executing broker. The prior small sale by an individual (Mark Hopman) is also reported. Given the small size relative to outstanding shares and the clear attestation, this filing appears to satisfy regulatory and governance expectations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 6002 El Tordo 2nd FL PO BOX 7297 Rancho Santa Fe CA 92067	16158	268376.10	43470125	08/19/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/19/2025	Stock Option	Beta Bionics			16158	08/19/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Mark Hopman 11 HUGHES Irvine CA 92618	Common	06/02/2025	868	15529.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What shares does the Form 144 for Beta Bionics (BBNX) propose to sell?

The notice proposes selling 16,158 common shares.

What is the reported aggregate market value and planned sale date?

Aggregate market value is $268,376.10 with an approximate sale date of 08/19/2025.

How were the securities being sold acquired?

They were acquired on 08/19/2025 via a stock option from Beta Bionics and payment is listed as cash.

Which broker is named to execute the sale?

The filing names Merrill Lynch (Rancho Santa Fe, CA address) as the broker.

Were there any related sales in the past three months disclosed?

Yes; Mark Hopman sold 868 common shares on 06/02/2025 for $15,529.00.